Cardinal Health’s pharmaceutical distribution contracts with OptumRx, a subsidiary of UnitedHealth Group, will not be renewed beyond June 2024. Despite this, Cardinal Health reaffirmed its fiscal 2024 adjusted EPS guidance and remains committed to its long-term growth targets. The company expects to partially offset the impact of OptumRx through new customer acquisitions and specialty growth.